Chelation Therapy Study
Chelation therapy has been proposed as the appropriate treatment for reducing the abnormal accumulation of essential heavy metals, such as Fe, Cu, and Zn, or nonessential and poisonous metals, such as lead (Pb), mercury (Hg), cadmium (Cd), and aluminum (Al). Toxic metals such as mercury and lead are thought to accelerate the aging process and correlate with cardiovascular disease. The human body cannot break down heavy metals, which can build up to toxic levels in the body and interfere with normal functioning. EDTA and other chelating drugs lower the blood levels of toxic metals such as lead, mercury and cadmium by attaching to the heavy metal molecules, which helps the body remove them through urination.In addition, the recent evidence indicates that chelation benefits patients, at least in part, by removing abnormal accumulation of essential nutritional trace elements from diseased organs and arterial walls.To get more news about Emeramide buy, you can visit fandachem.com official website.
Effective chelation treatment of metal poisoning requires more study to understand the physical and chemical characteristics of chelators and toxic metals, effective administration route and dosages of chelators, level of toxicity, and intra and extra cellular distributions.
The Riordan clinic has decades of experience using chelating agents to safely remove toxic minerals from the body. Our Bio-center laboratory is able to analyze mineral levels in hair, urine, and blood. Patients who have been treated for undergone heavy metal detoxification at the Riordan Clinic report improved memory, less fatigue, and other ‘wellness’ benefits. The Clinic’s approach to this point has been to treat with intravenous EDTA (ethylenediaminetetraacetic acid). Our Research Institute has been examining other chelating agents.
In a pilot clinical study using five rounds of chelation in five subjects, we compared chelation using intravenous EDTA to that using oral DMSA (dimercaptosuccinic acid). In our experiments, we examined urine levels of two-dozen different minerals. Our findings indicate that success (as indicated by increases in urinary mineral excretion) varies for different minerals. For example, EDTA was more successful in chelating cadmium and aluminum, while oral DMSA was more effective in chelating lead and arsenic. The results of this study have been published in peer-reviewed journals:
We have been examining the effects of toxic metals, and chelation therapy, on white blood cells. In the study described above, we found that chelation therapy increased lymphocyte and monocyte counts. In a separate set of experiments, we found that mercury (bound to organic molecules) is extremely toxic to stem cells in the laboratory. Lead, to a lesser extent, is also toxic to these cells. As stem cells are important in combating aging and repairing tissue damage, this suggests an additional mechanism by which toxic metals can affect health.
Because our interest in chelation therapy stems at least in part from its effect on the risk of cardiovascular illness, we developed a diagnostic technique to monitor the effect of treatments on cardiovascular risk factors. Our method, based on detection of circulating endothelial microparticles in blood samples, was published in journal:
